文献速递肝病消化道肿瘤与早癌

肝移植治疗肝内胆管癌:时机已成熟?

Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
PubMed 文献 · Hepatology · 2022-01-06

肝内胆管癌(iCCA)占所有胆管癌的20%,长期为肝移植(LT)的绝对禁忌证。近期回顾性分析提示,对高度选择的iCCA患者(如单发肿瘤≤2 cm且合并肝硬化不适合肝切除者),LT可能可行;目前有三项前瞻性试验正在进行。

要点

  • iCCA占全部胆管癌的20%,长期被视为肝移植绝对禁忌证。
  • 回顾性综述显示,对筛选后的小病灶iCCA患者,LT结果良好。
  • 目前有三项前瞻性试验正在进行,将明确LT在iCCA中的作用。

核心结论

  • 近期分析提示,对高度选择的iCCA患者,LT可能是潜在可行选择,但目前仍有三项前瞻性试验在进行以明确其作用。

研究设计与样本

  • 本文为综述,探讨已发表的LT治疗iCCA研究、正在进行的试验面临的挑战及未来机会。

主要发现

  • iCCA占所有胆管癌的20%,其余为肝外胆管癌(包括肝门部胆管癌[pCCA]和远端胆管癌)。
  • 多项回顾性综述显示,对筛选后的小病灶iCCA患者,LT结果良好。
  • 初步单中心报告描述了对局部晚期肿瘤经新辅助治疗有反应且疾病稳定一段时间的筛选患者进行LT。

关键数值与推荐

  • LT主要适用于两种临床场景:一是极早期疾病(单发肿瘤,≤2 cm)合并肝硬化且不适合肝切除的患者。
  • 二是局部晚期iCCA但肝切除范围过大不可行的患者。
  • 目前有三项前瞻性试验正在进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cholangiocarcinoma (CCA) represents the second-most common primary liver malignancy after HCC and has risen in incidence globally in the past decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all CCAs, with the rest being extrahepatic (including perihilar [pCCA] and distal CCA). Though long representing an absolute contraindication for liver transplantation (LT), recent analyses of outcomes of LT for iCCA have suggested that iCCA may be a potentially feasible option for highly selected patients. This has been motivated both by successes noted in outcomes of LT for other malignancies, such as HCC and pCCA, and by several retrospective reviews demonstrating favorable results with LT for a selected group of iCCA patients with small lesions. LT for iCCA is primarily relevant within two clinical scenarios. The first includes patients with very early disease (single tumor, ≤2 cm) with cirrhosis and are not candidates for liver resection (LR). The second scenario is patients with locally advanced iCCA, but where the extent of LR would be too extensive to be feasible. Preliminary single-center reports have described LT in a selected group of patients with locally advanced tumors who have responded to neoadjuvant therapy and have a period of disease stability. Currently, there are three prospective trials underway that will help clarify the role of LT in iCCA. This review seeks to explore the available studies involving LT for iCCA, the challenges of ongoing trials, and opportunities for the future.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sapisochin G, Ivanics T, Heimbach J, et al. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time? Hepatology. 2022. PMID: 34859465. doi:10.1002/hep.32258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。